Bichat hospital
Paris, 75018, France
NCT Number: NCT03655730
Suicide is the third leading cause of death in adolescents and young adults in the United States and the second leading cause in European countries.
Depressive disorders are consistently the most prevalent psychiatric disorder among adolescents who attempt suicide with a prevalence ranging from 49% to 64%. Depression in adolescent and young adults is a multifactorial phenomenon, as is the risk of suicidal attempt. To address such problems, effective and accessible treatment is needed, as recommended by the French Health Authority (HAS).
Our primary objective is to demonstrate that a weekly psychotherapeutic intervention reduces the depression level.
The primary assessment criterion is the variation of the clinician Adolescent Depression Rating Scale (ADRSc) from randomisation to month 6.
The study also aims comparing in the 2 randomised groups
* ADRS depression global score (clinician and subject) at 0, 3, 9 and 12 months * Number of suicidal attempts and self-harm attempts at 6 and 12 months * Number of drop-out at 6 and 12 months * Beck's Hopelessness Scale at 0, 3, 6, 9 and 12 months * Global score on the GHQ-28 and scores on the 4 subscales (Somatization, Anxiety and Insomnia, Social dysfunction, Depressive mood) at 0, 3, 6, 9 and 12 months. * Working AIliance Inventory (WAI) score at 0, 3, 6, 9 and 12 months
Looking for future studies?
Notify Me16 year–25 year
All sexes
Interventional
Not applicable
Paris, 75018, France
Suicide is the third leading cause of death in adolescents and young adults in the United States and the second leading cause in European countries. In France, recent epidemiological data showed that the suicide rate in adolescents aged 15 to 19 is 4.1/100 000 inhabitants. Prevalence of suicidal ideations ranges from 15 to 25% in the general population and lifetime estimates of suicide attempts among adolescents range from 1.3 to 3.8% in males and from 1.5 to 10.1% in females. Reducing suicide and suicide attempts is therefore a key public health target.
Depressive disorders are consistently the most prevalent psychiatric disorder among adolescents who attempt suicide with a prevalence ranging from 49% to 64%. Depression in adolescent and young adults is a multifactorial phenomenon, as is the risk of suicidal attempt.
Being in a situation of failure at school or not having a clear training or work project clearly increases the risk for depression. Some studies have targeted potential high school drop outs as a target for prevention of suicidality.
To address such problems, effective and accessible treatment is needed, as recommended by the French Health Authority (HAS). However, only few studies assess, through a randomized protocol, efficacity and feasibility of psychotherapeutic treatment in psychiatry in general and particularly in this population, although individual psychotherapy is highly recommended in clinical practice for depressed adolescents and young adults.
Our primary objective is to demonstrate that a weekly psychotherapeutic intervention reduces the depression level.
The primary assessment criterion is the variation of the clinician Adolescent Depression Rating Scale (ADRSc) from randomisation to month 6.
Others objectives are the following :
To compare in the 2 randomised groups
To describe, in the whole sample (randomised and not randomised),
To evaluate the sensitivity to change of the French version of the ADRSc.
330 subjects wil be included to have 132 randomized subjects into two arms: sustained psychotherapeutic intervention or usual care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Randomisation criteria :
Included subjects will be randomised if at least one of the following conditions is met: baseline ADRSc score greater or equal than 8 or abuse and/or deprivation according to the Childhood Trauma Questionnaire (CTQ, short version):
weekly psychotherapeutic individual sessions following the IPT method during one year
the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
Time frame: 6 months
Defined as the difference of ADRS clinician score (cf. Appendix 18.2.1) between inclusion and 6 month.
Time frame: at 0, 3, 9 and 12 months
The ADRSc (clinician) questionnaire will be filled out by the assessor at 0, 3 and 9 and 12 months during follow-up visits
Time frame: at 6 and 12 months
The number of suicidal attempts and self-harm attempts, at 6 and 12 months
Time frame: at baseline, 6 and 12 months
The number of drop outs at baseline, 6 and 12 months
Time frame: t 0, 3, 6, 9 and 12 months
The evolution on time of the hopelessness, assessed at 0, 3, 6, 9 and 12 months
Time frame: at 0, 3, 6, 9 and 12 months
Time frame: at 0, 3, 6, 9 and 12 months
The evolution on time of the working aIliance at 0, 3, 6, 9 and 12 months
Assistance Publique - Hôpitaux de Paris
Other
Efficacity of a Sustained Weekly Psychological Intervention for Adolescents and Young Adults Attending to Local Missions for Reinsertion, on Reducing the Suicidal Ideations, Depression Level and Improving Reinsertion Compared to Usual Care
Acronym: MLADO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05925816
Behavior, Behavioral Symptoms
Annandale-on-Hudson, New York, United States
View Trial DetailsNCT04837573
Behavior, Behavioral Symptoms
Los Angeles, California, United States
View Trial DetailsNCT05619510
Behavior, Behavioral Symptoms
Baltimore, Maryland, United States
View Trial Details